---

Tocilizumab as a breakthrough in the cytokine storm of COVID-19 pneumonia- Case series in the intensive care unit

Full Text PDF Share on Facebook Share on Twitter

---

Case Series

Author Details : Michell Gulabani*, Richa Chauhan, Ashok Kumar Saxena

Volume : 9, Issue : 3, Year : 2022

Article Page : 382-386

https://doi.org/10.18231/j.ijca.2022.076

Suggest article by email

Get Permission

Abstract

Tocilizumab (TCZ) is a promising treatment for management of COVID-19 pneumonia amid many controversies linked to its potential benefit. The exact time for administration of the drug to avail maximum clinical benefit is still unclear. We present a case series in which three patients with severe COVID 19 (respiratory rate of more than 30/min, breathlessness and hypoxia with Spo2<92>75 mg/dl, IL-6 > 200 pg/ml and ABG depicted falling trend in Pao2/Fio2 ratio despite adequate ventilation. These patients received TCZ nearly 9to 14 days of ICU stay after excluding secondary bacterial and fungal infections (sputum, urine and blood culture) as their inflammatory markers increased suddenly during the late phase of the disease. Their liver and kidney functions were acceptable and no neutropenia or thrombocytopenia was ensured. Their inflammatory markers improved significantly post intervention and they weaned from non-invasive ventilation, transferred from the intensive care unit to the ward and later discharged in 20-25 days from the hospital.Therefore, we would like to emphasize consideration of TCZ in worsening critically ill COVID-19 patients as a pharmacological modality even during late phase of the disease as a means to improve oxygenation, avoiding mechanical ventilation and subsequent morbidity and mortality. COVID 19 is a dynamically evolving disease and new treatment modalities at the different stages of the disease may yield benefits in certain sub-groups of patients.
 

Keywords: Tocilizumab, Cytokine storm, Interleukin­ 6, COVID­ 19.

How to cite : Gulabani M, Chauhan R, Saxena A K, Tocilizumab as a breakthrough in the cytokine storm of COVID-19 pneumonia- Case series in the intensive care unit. Indian J Clin Anaesth 2022;9(3):382-386

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.